Search

Fluorocholine F-18

Rabies immune globulin, equine

Dirucotide

Dirucotide has been developed for the treatment of multiple sclerosis (MS). Developed at the University of Alberta, dirucotide is being investigated by BioMS Medical Corp.

Ferrous bisglycinate

It is found in foods for food enrichment or in supplements for the treatment of iron deficiency or iron deficiency anemia.

Avobenzone

It is included in many commercially available sunscreens which are used as wide spectrum sunscreens. … It is oil soluble ingredient. Avobenzone has the ability to absorb ultraviolet light over wider range of wavelengths.

Tetanus immune globulin, equine

Nifurtimox

On August 6 2020, accelerated FDA approval was granted for its use in pediatric patients in response to promising results from phase III clinical trials. … Continued approval will be contingent upon confirmatory data.

Talimogene laherparepvec

It is a genetically administered herpes simplex virus 1 (HSV-1) that expresses human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with antitumor and immune-stimulating activities. … It specifically replicates within tumor cells and causes lysis. It was approved by the FDA in 2015 under the market name Imlygic.

Ancestim

Ancestim was developed by Amgen and sold to Biovitrium in December 2008. It was submitted to the FDA under the status of recommendation for approval with a 10 to 1 votes. … It is a 166 amino acid protein produced by E. coli with an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal

Lonafarnib

[L23414, L23544] Lonafarnib was granted FDA approval on November 20, 2020, and is the first FDA-approved treatment for HGPS and other related progeroid laminopathies.[L23414, L23549] … Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature